#USA #New York #Class Action #Securities Fraud #Skye Bioscience

Skye Bioscience Investors: Important Legal Notice

On December 2, 2025, a crucial announcement was made by Levi & Korsinsky, LLP regarding the ongoing legal matters surrounding Skye Bioscience, Inc. (NASDAQ: SKYE). Investors in Skye Bioscience are encouraged to contact the law firm to discuss their rights related to a class action securities lawsuit. This case seeks to address significant losses experienced by shareholders as a result of potential securities fraud.

Background of the Case

The lawsuit aims to represent those who suffered financial losses during the period from November 4, 2024, to October 3, 2025. During this timeframe, investors faced a startling revelation when it became apparent that Skye Bioscience's lead product candidate, nimacimab, was not as effective as portrayed by the company's defendants. This discrepancy raises serious concerns about the validity of the company’s public statements regarding nimacimab's effectiveness and its potential in the clinical and commercial landscape, which were allegedly overstated.

The items mentioned in the complaint include:
1. Misleading Effectiveness Claims: Assertions made about nimacimab’s efficacy were deemed misleading, thereby affecting investor decisions.
2. Exaggerated Commercial Prospects: The suit suggests that the company overestimated the product's potential in the marketplace, misleading shareholders about its future performance.
3. Material Misstatements: It is asserted that the public statements made by the company's executives were materially false and misleading at all relevant times.

Deadlines and Participation Details

Investors affected by these alleged misrepresentations have a limited time frame to act. Those wishing to pursue claims must do so by January 16, 2026. Notably, potential class members do not need to serve as lead plaintiffs to share in any recovery that may result from the proceedings.

Levi & Korsinsky guarantees that participation in the class action will not incur any out-of-pocket costs, providing an opportunity for investors to recover losses without financial burden. This initiative underscores the law firm’s commitment to safeguarding shareholders’ rights and maximizing their potential for recovery in securities fraud cases.

Why Choose Levi & Korsinsky?

For over two decades, Levi & Korsinsky has proven instrumental in securing substantial financial compensation for aggrieved shareholders. With a well-established track record in litigating complex securities cases, the firm has gained recognition, ranking in the top tier by ISS Securities Class Action Services for seven consecutive years. Their team comprises over 70 dedicated professionals committed to serving their clients effectively.

Next Steps for Investors

Investors in Skye Bioscience who feel they have been wronged are encouraged to reach out directly to Levi & Korsinsky for more information. Joseph E. Levi, Esq. is available for inquiries at (212) 363-7500 or via email at [email protected]. Potential claimants can also submit their information through the dedicated class action form on the firm's website.

As many investors may not yet be aware of their rights or the specifics of the situation, this is a crucial time for action. Eligible investors should not hesitate to get involved to ensure their interests are protected in the unfolding legal process surrounding Skye Bioscience, Inc.

This announcement symbolizes a pivotal moment for investors, marking a fierce stance against corporate misconduct and the commitment to holding entities accountable. The legal firm stands ready to assist those impacted in obtaining justice and addressing their financial losses strategically.